Novo Nordisk launches first and only multi-month subscription program for FDA-approved Wegovy®, offering savings of up to $1,200/year
PLAINSBORO, N.J., March 31, 2026 /PRNewswire/ -- Novo Nordisk today announced a new multi-month subscription program for Wegovy ® (semaglutide) that provides eligible self-pay patients who enroll in the program through select telehealth providers a lower, predictable monthly price. The program is designed to reduce cost uncertainty and help people start and stay on FDA-approved obesity treatment.
"The new Wegovy ® subscription program removes barriers, providing people who enroll a simple, affordable, and consistent way to start and stay on genuine, FDA-approved treatment," said Ed Cinca, senior vice president, Marketing & Patient Solutions at Novo Nordisk. "By providing predictable monthly pricing, multi-month options, and access through trusted telehealth providers, this program aims to support a more manageable way for people to stay on treatment and focus on achieving meaningful, sustainable weight loss outcomes."
Novo Nordisk Subscription program details
This first and only subscription program for FDA-approved Wegovy ® will be available beginning March 31, 2026, through Ro, WeightWatchers, LifeMD, with Hims & Hers, Sesame, and others to follow soon. Patients can save up to $600/year on the Wegovy ® pill and up to $1,200/year on the Wegovy ® injection with a 12-month subscription and should contact their telehealth providers directly for eligibility and enrollment details.
Eligible self-pay patients can choose 3-, 6- or 12-month subscriptions, with longer subscription periods offering lower monthly pricing:
Wegovy ® pen (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg)*
Wegovy ® pill (9 mg and 25 mg doses)**
*Wegovy HD (semaglutide) injection 7.2 mg will be added at a later date.
**Self-pay patients pay $149 for each month of 1.5 mg and 4 mg. 4 mg offer available until August 31, 2026, then $199 per month for 4 mg.
Limited-time offers are separate and distinct and not included in monthly subscriptions. Patients should contact their telehealth provider directly for complete program terms, as these vary by platform.
Obesity is a chronic disease that requires ongoing management under the care of a healthcare professional. The subscription model is designed to help support people living with obesity by providing greater cost predictability and encouraging treatment consistency so that people focus on their long-term weight management goals in partnership with their healthcare teams.
In addition to working with select telehealth providers, Wegovy ® is available through a range of additional access points, including more than 70,000 US pharmacies and NovoCare ® Pharmacy. Those with commercial insurance coverage can access Wegovy ® for as little as $25 per month through existing savings programs.
About obesity
Obesity is a serious, chronic, progressive, and complex disease that requires long-term management. 1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off. 1,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment. 4,5
About Novo Nordisk
Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs approximately 10,000 people throughout the country across more than 10 manufacturing, R&D and corporate locations in seven states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
What is Wegovy ®?
Wegovy ® (semaglutide) injection is a prescription medicine used with a reduced-calorie diet and increased physical activity to:
Wegovy ® (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to:
Wegovy ® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines.
It is not known if Wegovy ® injection is safe and effective:
It is not known if Wegovy ® tablets are safe and effective for use in people under 18 years of age.
Important Safety Information
What is the most important information I should know about Wegovy ®?
Wegovy ® may cause serious side effects, including:
Do not use Wegovy ® if:
Before using Wegovy ®, tell your healthcare provider if you have any other medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy ® may affect the way some medicines work and some medicines may affect the way Wegovy ® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy ® slows stomach emptying and can affect medicines that need to pass through the stomach quickly.
What are the possible side effects of Wegovy ®?
Wegovy ® may cause serious side effects, including:
The most common side effects of Wegovy ® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss.
Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy ®.
Contacts for further information
Media:
Liz Skrbkova (US)
+1 609 917 0632
[email protected]
Ambre James-Brown (Global)
+45 3079 9289
[email protected]
Investors:
Frederik Taylor Pitter (US)
+1 609 613 0568
[email protected]
Michael Novod (Global)
+45 3075 6050
[email protected]
Jacob Martin Wiborg Rode (Global)
+45 3075 5956
[email protected]
Sina Meyer (Global)
+45 3079 6656
[email protected]
Max Ung (Global)
+45 3077 6414
[email protected]
Christoffer Sho Togo Tullin (Global)
+45 3079 1471
[email protected]
Alex Bruce (Global)
+45 3444 2613
[email protected]
References:
SOURCE Novo Nordisk